12.21 USD
-0.04 (-0.33%)
12.21 USD
0 (0%)
We assign a fundamental rating of 5 out of 10 to AMRX. AMRX was compared to 191 industry peers in the Pharmaceuticals industry. AMRX has only an average score on both its financial health and profitability. A decent growth rate in combination with a cheap valuation! Better keep an eye on AMRX.
1. Profitability
1.1 Basic Checks
In the past year AMRX was profitable.
In the past year AMRX had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: AMRX reported negative net income in multiple years.
AMRX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
AMRX's Return On Assets of 0.16% is fine compared to the rest of the industry. AMRX outperforms 77.49% of its industry peers.
AMRX has a better Return On Invested Capital (10.43%) than 89.53% of its industry peers.
The Average Return On Invested Capital over the past 3 years for AMRX is below the industry average of 12.85%.
The last Return On Invested Capital (10.43%) for AMRX is above the 3 year average (7.98%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.16% | ||
| ROE | N/A | ||
| ROIC | 10.43% |
ROA(3y)-3.06%
ROA(5y)-1.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.98%
ROIC(5y)6.53%
1.3 Margins
Looking at the Profit Margin, with a value of 0.20%, AMRX is in the better half of the industry, outperforming 77.49% of the companies in the same industry.
The Operating Margin of AMRX (12.32%) is better than 85.34% of its industry peers.
AMRX's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 36.76%, AMRX is in line with its industry, outperforming 59.16% of the companies in the same industry.
In the last couple of years the Gross Margin of AMRX has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.32% | ||
| PM (TTM) | 0.2% | ||
| GM | 36.76% |
OM growth 3Y6.45%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y4.39%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AMRX is still creating some value.
The number of shares outstanding for AMRX has been reduced compared to 1 year ago.
Compared to 5 years ago, AMRX has more shares outstanding
AMRX has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 1.87 indicates that AMRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
AMRX has a Altman-Z score (1.87) which is in line with its industry peers.
AMRX has a debt to FCF ratio of 11.13. This is a negative value and a sign of low solvency as AMRX would need 11.13 years to pay back of all of its debts.
AMRX's Debt to FCF ratio of 11.13 is fine compared to the rest of the industry. AMRX outperforms 78.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 11.13 | ||
| Altman-Z | 1.87 |
ROIC/WACC1.01
WACC10.3%
2.3 Liquidity
A Current Ratio of 2.13 indicates that AMRX has no problem at all paying its short term obligations.
AMRX has a Current ratio (2.13) which is in line with its industry peers.
AMRX has a Quick Ratio of 1.42. This is a normal value and indicates that AMRX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.42, AMRX is doing worse than 64.40% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.13 | ||
| Quick Ratio | 1.42 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 25.00% over the past year.
Measured over the past years, AMRX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 10.63% on average per year.
The Revenue has grown by 16.73% in the past year. This is quite good.
AMRX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.43% yearly.
EPS 1Y (TTM)25%
EPS 3Y-11.61%
EPS 5Y10.63%
EPS Q2Q%6.25%
Revenue 1Y (TTM)16.73%
Revenue growth 3Y10.1%
Revenue growth 5Y11.43%
Sales Q2Q%11.68%
3.2 Future
AMRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.95% yearly.
Based on estimates for the next years, AMRX will show a small growth in Revenue. The Revenue will grow by 0.60% on average per year.
EPS Next Y40.69%
EPS Next 2Y28.74%
EPS Next 3Y24.22%
EPS Next 5Y11.95%
Revenue Next Year8.74%
Revenue Next 2Y7.7%
Revenue Next 3Y7.47%
Revenue Next 5Y0.6%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 16.28 indicates a correct valuation of AMRX.
AMRX's Price/Earnings ratio is rather cheap when compared to the industry. AMRX is cheaper than 85.34% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.54, AMRX is valued a bit cheaper.
Based on the Price/Forward Earnings ratio of 12.70, the valuation of AMRX can be described as correct.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AMRX indicates a rather cheap valuation: AMRX is cheaper than 83.77% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.78, AMRX is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.28 | ||
| Fwd PE | 12.7 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AMRX indicates a rather cheap valuation: AMRX is cheaper than 86.39% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, AMRX is valued cheaper than 84.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.23 | ||
| EV/EBITDA | 10.44 |
4.3 Compensation for Growth
AMRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of AMRX may justify a higher PE ratio.
A more expensive valuation may be justified as AMRX's earnings are expected to grow with 24.22% in the coming years.
PEG (NY)0.4
PEG (5Y)1.53
EPS Next 2Y28.74%
EPS Next 3Y24.22%
5. Dividend
5.1 Amount
AMRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
12.21
-0.04 (-0.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners45.3%
Inst Owner Change6.11%
Ins Owners46.29%
Ins Owner Change-4.88%
Market Cap3.84B
Revenue(TTM)2.93B
Net Income(TTM)5.90M
Analysts82
Price Target13.6 (11.38%)
Short Float %4.21%
Short Ratio3.92
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.63%
Min EPS beat(2)21.21%
Max EPS beat(2)40.06%
EPS beat(4)3
Avg EPS beat(4)19.7%
Min EPS beat(4)-22.85%
Max EPS beat(4)40.37%
EPS beat(8)7
Avg EPS beat(8)26.2%
EPS beat(12)11
Avg EPS beat(12)30.21%
EPS beat(16)11
Avg EPS beat(16)19.73%
Revenue beat(2)0
Avg Revenue beat(2)-2.51%
Min Revenue beat(2)-4.6%
Max Revenue beat(2)-0.41%
Revenue beat(4)1
Avg Revenue beat(4)-2.13%
Min Revenue beat(4)-4.71%
Max Revenue beat(4)1.22%
Revenue beat(8)3
Avg Revenue beat(8)-0.67%
Revenue beat(12)7
Avg Revenue beat(12)0.45%
Revenue beat(16)8
Avg Revenue beat(16)-0.15%
PT rev (1m)11.11%
PT rev (3m)11.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14.29%
EPS NY rev (1m)0.11%
EPS NY rev (3m)7.38%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.58%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.39%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.28 | ||
| Fwd PE | 12.7 | ||
| P/S | 1.31 | ||
| P/FCF | 16.23 | ||
| P/OCF | 11.71 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.44 |
EPS(TTM)0.75
EY6.14%
EPS(NY)0.96
Fwd EY7.87%
FCF(TTM)0.75
FCFY6.16%
OCF(TTM)1.04
OCFY8.54%
SpS9.34
BVpS-0.35
TBVpS-4.11
PEG (NY)0.4
PEG (5Y)1.53
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.16% | ||
| ROE | N/A | ||
| ROCE | 13.2% | ||
| ROIC | 10.43% | ||
| ROICexc | 11.26% | ||
| ROICexgc | 21.11% | ||
| OM | 12.32% | ||
| PM (TTM) | 0.2% | ||
| GM | 36.76% | ||
| FCFM | 8.06% |
ROA(3y)-3.06%
ROA(5y)-1.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.98%
ROIC(5y)6.53%
ROICexc(3y)8.26%
ROICexc(5y)6.86%
ROICexgc(3y)18.59%
ROICexgc(5y)15.87%
ROCE(3y)10.57%
ROCE(5y)8.54%
ROICexgc growth 3Y25.12%
ROICexgc growth 5YN/A
ROICexc growth 3Y27.15%
ROICexc growth 5YN/A
OM growth 3Y6.45%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y4.39%
F-Score7
Asset Turnover0.82
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 11.13 | ||
| Debt/EBITDA | 4.36 | ||
| Cap/Depr | 37.95% | ||
| Cap/Sales | 3.11% | ||
| Interest Coverage | 1.67 | ||
| Cash Conversion | 54.45% | ||
| Profit Quality | 4008.53% | ||
| Current Ratio | 2.13 | ||
| Quick Ratio | 1.42 | ||
| Altman-Z | 1.87 |
F-Score7
WACC10.3%
ROIC/WACC1.01
Cap/Depr(3y)33.21%
Cap/Depr(5y)30.06%
Cap/Sales(3y)3.22%
Cap/Sales(5y)3.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25%
EPS 3Y-11.61%
EPS 5Y10.63%
EPS Q2Q%6.25%
EPS Next Y40.69%
EPS Next 2Y28.74%
EPS Next 3Y24.22%
EPS Next 5Y11.95%
Revenue 1Y (TTM)16.73%
Revenue growth 3Y10.1%
Revenue growth 5Y11.43%
Sales Q2Q%11.68%
Revenue Next Year8.74%
Revenue Next 2Y7.7%
Revenue Next 3Y7.47%
Revenue Next 5Y0.6%
EBIT growth 1Y26.75%
EBIT growth 3Y17.2%
EBIT growth 5YN/A
EBIT Next Year13.19%
EBIT Next 3Y10.22%
EBIT Next 5Y3.87%
FCF growth 1Y72%
FCF growth 3Y5.18%
FCF growth 5YN/A
OCF growth 1Y75.78%
OCF growth 3Y6.86%
OCF growth 5Y180.48%
AMNEAL PHARMACEUTICALS INC / AMRX FAQ
What is the fundamental rating for AMRX stock?
ChartMill assigns a fundamental rating of 5 / 10 to AMRX.
What is the valuation status of AMNEAL PHARMACEUTICALS INC (AMRX) stock?
ChartMill assigns a valuation rating of 8 / 10 to AMNEAL PHARMACEUTICALS INC (AMRX). This can be considered as Undervalued.
How profitable is AMNEAL PHARMACEUTICALS INC (AMRX) stock?
AMNEAL PHARMACEUTICALS INC (AMRX) has a profitability rating of 6 / 10.
What is the financial health of AMNEAL PHARMACEUTICALS INC (AMRX) stock?
The financial health rating of AMNEAL PHARMACEUTICALS INC (AMRX) is 4 / 10.
What is the earnings growth outlook for AMNEAL PHARMACEUTICALS INC?
The Earnings per Share (EPS) of AMNEAL PHARMACEUTICALS INC (AMRX) is expected to grow by 40.69% in the next year.